AlphAIalphai — Financial news for AI agents
investing.comAUG 192 min read$MRNA

Moderna shares surge as melanoma vaccine with Merck succeeds in large trial

Moderna and Merck announced positive interim results from a late-stage trial of their melanoma vaccine, Intismeran, combined with Keytruda. The treatment met primary and secondary goals, reducing cancer recurrence and spread. Moderna's shares surged 60% premarket, while Merck rose 7.5%. Analysts expect the therapy could generate $3 billion by 2035. The trial involved 1,137 high-risk melanoma patients.

Original reporting
investing.com
Published Aug 19, 2026, 12:12 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 12:36 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefTechnology
Primary signal
$MRNA
Bullish
high confidence
Mentioned
$MRNA · $MRK
Relevance
9/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$MRNABullishHigh
01

Why it matters

The trial met primary and secondary endpoints, prompting a sharp stock rally for both companies.

02

Market read

First‑time disclosure of pivotal trial data for a large‑cap biotech partnership, driving significant price moves.

03

What to watch

Regulatory timeline and potential competition from other mRNA cancer candidates could temper upside.

Relevance 9/10Novelty 9/10Timing: premarket trading

Background

Moderna and Merck disclosed interim results of a late‑stage melanoma vaccine trial, the first public release of this data.

Company-level read

Ticker impact

$MRNABullishHigh confidence
Context

Moderna announced positive interim results for its melanoma vaccine trial, sending the stock up 60% pre‑market.

Expected impact

Further upside if full data confirm efficacy; near‑term volatility expected.

Evidence & confidence

First disclosure of pivotal trial data for a large‑cap biotech; market reacted strongly.

$MRKBullishHigh confidence
Context

Merck's Keytruda combined with Moderna's vaccine showed efficacy, lifting Merck shares 7.5% pre‑market.

Expected impact

Potential incremental upside as partnership gains traction.

Evidence & confidence

First report of trial success involving Merck; market response confirms material impact.

Market effects

Sector

Strengthens biotech and oncology sectors, may lift peers developing mRNA cancer vaccines.

Regional

Positive for US biotech market; limited immediate effect elsewhere.

Global

Highlights mRNA platform versatility, could influence global pharma collaborations.

Counterpoint

What could challenge this read

Skeptics may question durability of interim data and long‑term safety, suggesting caution.

Key entities

  • Company
    Moderna

    mRNA vaccine developer

  • Company
    Merck

    Immunotherapy leader, maker of Keytruda

Read at source← All news

Also covered by

2 outlets

Related articles

AUG 21
$MRNAHighAI 8/10

Time High on 10.32% Session After Moderna Phase 3 Win

ARK Genomic Revolution ETF (ARKG) surged 10.32% to a record $47.67 after Moderna and Merck's mRNA cancer therapy succeeded in a Phase 3 trial. Moderna rose 177% to $174.38, Merck gained 13%. ARKG's top holdings, including Tempus AI (+23.91%), drove gains. The fund is up 64% YTD, 90% in 12 months.

tradingnews.com3 min
AUG 21
$MRKHighAI 8/10

Why Is Merck Stock Still An Undervalued Mega-Cap In Pharma?

Merck (MRK) stock surged 73% in the past year, outpacing the S&P 500, driven by successful clinical trials and FDA approvals. The company's pipeline, including LIPFENDRA and an mRNA cancer vaccine, addresses concerns about KEYTRUDA's patent expiration. Merck's forward P/E of 16x is lower than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY), suggesting potential undervaluation.

forbes.com2 min
AUG 21
$ROSTMed

Stocks making the biggest moves midday: Moderna, Robinhood, BJ's Wholesale, Coinbase & more

BJ's Wholesale shares rose 4% after Q2 earnings beat estimates, with revenue at $6.09B and EPS guidance raised. Ross Stores also gained over 4% on strong Q2 results and upbeat Q3 guidance. Crypto-related stocks like Robinhood and Coinbase surged as bitcoin climbed over 20% for the week. Broadcom rose 1% on reports of a $60B debt plan for a deal. OSI Systems dropped 10% after missing revenue expectations. The Boston Beer Company fell 3% following CFO departure news. O-I Glass jumped 10% after a C

cnbc.com3 min
AUG 21
$MRNAHighAI 9/10

After Moderna’s Big News, Here Are Three Biotechs to Watch

Moderna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.

pro.thestreet.com3 min
AUG 21
$MRKMedAI 8/10

Merck stock analysis: great pipeline at a stretched valuation

Merck (MRK) hit an all-time high of $153.53, up 78% in a year, after positive Phase 3 results for its mRNA cancer therapy with Moderna. Analysts are divided, with Goldman Sachs raising its target to $160 and UBS downgrading to Neutral at $150. Merck's revenue grew from $48.7B (2021) to $65.0B (2025), but it trades 7.5% above fair value with a high P/E of 55.2x. The stock is in overbought territory, with technical indicators suggesting potential exhaustion.

investing.com3 min
AUG 21
$MRNAMedAI 8/10

A ‘pivotal moment’ for personalised cancer vaccines

Moderna and Merck announced positive final-stage trial results for a personalized mRNA cancer vaccine, showing increased cancer-free survival in melanoma patients when combined with Keytruda. The vaccine, tailored to each patient's tumor, uses mRNA technology. Moderna's shares surged, but experts caution pending full data release and peer review. The companies are also testing similar vaccines for other cancers.

theweek.com3 min